263 related articles for article (PubMed ID: 15860854)
1. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
[TBL] [Abstract][Full Text] [Related]
2. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
Mansi JL; Yellowlees A; Lipscombe J; Earl HM; Cameron DA; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Evans TR
Breast Cancer Res Treat; 2010 Aug; 122(3):787-94. PubMed ID: 20559708
[TBL] [Abstract][Full Text] [Related]
3. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Bear HD; Anderson S; Brown A; Smith R; Mamounas EP; Fisher B; Margolese R; Theoret H; Soran A; Wickerham DL; Wolmark N;
J Clin Oncol; 2003 Nov; 21(22):4165-74. PubMed ID: 14559892
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
6. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
7. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
Lee KS; Ro J; Nam BH; Lee ES; Kwon Y; Kwon HS; Chung KW; Kang HS; Kim EA; Kim SW; Shin KH; Kim SK
Breast Cancer Res Treat; 2008 Jun; 109(3):481-9. PubMed ID: 17653851
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A; Lauschner I; Ruiz A; Guerrero A; Sánchez-Rovira P; Seguí MA; Goerke K; Wolf M; Manikhas AG; Wacker J; Marmé F; Lichter P; Sinn HP; Sohn C; Mansouri K; Bauknecht T; Hahn M
Clin Breast Cancer; 2007 Apr; 7(7):555-8. PubMed ID: 17509164
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
15. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
O'Regan RM; Von Roenn JH; Carlson RW; Malik U; Sparano JA; Staradub V; Khan S; Jovanovic B; Morrow M; Gradishar WJ
Clin Breast Cancer; 2005 Jun; 6(2):163-8. PubMed ID: 16001995
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
18. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
Jacot W; Bibeau F; Gourgou-Bourgade S; Gutowski M; Colombo PE; Bleuse JP; Kramar A; Romieu G
Am J Clin Oncol; 2010 Dec; 33(6):544-9. PubMed ID: 20042972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
